Risankizumab-RZAA Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Risankizumab-RZAA Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
90
Registered trials
218
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Risankizumab-RZAA can convert its Monoclonal antibody profile and IL-23p19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Risankizumab-RZAA (query alias: risankizumab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-23p19; IL-23p19 inhibitors |
| Highest global status | Approved |
| Originator | AbbVie, Inc. |
| Active developers | Boehringer Ingelheim Pharma GmbH & Co., KG, AbbVie, Inc., AbbVie Deutschland GmbH & Co. KG |
The MCP disease footprint includes Crohn's disease, active moderate, Crohn's disease, active severe, Colitis, Ulcerative. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07499232 | Phase 3 | Recruiting | 530 | Number of Participants with Deep Remission at Week 52 |
| NCT07697456 | Phase 2 | Not yet recruiting | 2000 | Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission |
| NCT07466550 | Phase 1 | Recruiting | 60 | Number of Participants with Adverse Events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial
Phase 4; n=150; evaluation: Positive. Reported fields: PASI100 = 6.5 % ; PASI100 = 27.5 %
Effect of Risankizumab Versus Deucravacitinib on Psoriasis-Related Symptoms and Quality of Life in Patients With Moderate Plaque Psoriasis: Results From the IMMpactful Trial at Week 16
Phase 3; n=393; evaluation: Positive. Reported fields: DLQI 0/1 = 30.5 % ; DLQI 0/1 = 64.1 %
Long-Term Safety Assessment of Risankizumab in Psoriatic Disease: An Integrated Interval Analysis of Clinical Trial Data
Not Applicable; n=5832; evaluation: Positive. Reported fields: Malignancies(excluding NMSC) = 0.3 events/100 person-years ; Malignancies(excluding NMSC) = In PsO, Malignancy rates excluding NMSC remained stable around 0.4 E/100PY up to 4.5 years, then increased from 1.0 to 1.7/100PY (95% CI: 0.5 3.9); however, cumulative rates (0.6/100PY [95% CI: 0.5 0.8]) remained within reference benchmarks (0.5 0.8/100PY). events/100 person-years
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Risankizumab-RZAA addresses Crohn's disease, active moderate, Crohn's disease, active severe, Colitis, Ulcerative. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2016-03-07 | AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds | Phase 1 | US$595.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
